비교리스트

 카트 문의
시장보고서
상품코드
1531041

간세포 성장인자(HGFs) 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Hepatocyte Growth Factors (HGFs) Market (Type: Phase III [Ongoing], Phase II [Approved], Phase II [Ongoing], Phase I, and Preclinical) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 141 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

간세포 성장인자(HGFs) 시장 - 조사 범위

TMR의 조사 보고서 "간세포 성장인자(HGFs) 세계 시장"은 2024년부터 2034년까지 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고 있습니다. 이 보고서는 2024년을 기준 연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지의 세계 간세포 성장인자(HGFs) 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 간세포 성장인자(HGFs) 시장의 연평균 복합 성장률(CAGR %)도 제시합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 애널리스트는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 자료 등을 참고하여 간세포 성장인자(HGFs) 시장을 추론했습니다.

시장 스냅샷
2023년 시장 규모 7,030만 달러
2034년 시장 규모 1억 4,100만 달러
CAGR 6.5%

이 보고서는 세계 간세포 성장인자(HGFs) 시장의 경쟁 환경을 조사하고 있습니다. 세계 간세포 성장인자(HGFs) 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 회사 개요, 재무 상태, 최근 동향, SWOT 등은 세계 간세포 성장인자(HGFs) 시장 기업의 속성 중 일부로 이 보고서에서 다루고 있습니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 시장

제4장 시장 개요

  • 소개
  • 개요
  • 시장 역학
  • 시장 분석과 예측, 2020-2034년

제5장 주요 인사이트

  • 파이프라인 분석
  • 주요 제품·브랜드 분석
  • 주요 M&A
  • COVID-19에 의한 산업에 대한 영향

제6장 세계의 시장 분석과 예측 : 유형별

  • 소개와 정의
  • 주요 조사 결과·발전
  • 시장 금액 예측 : 유형별, 2020-2034년
    • 단계 III(진행중)
    • 단계 II(승인된)
    • 단계 II(진행중)
    • 단계 I
    • 전임상
  • 시장 매력 분석 : 유형별

제7장 세계의 시장 분석과 예측 : 용도별

  • 소개와 정의
  • 주요 조사 결과·발전
  • 시장 금액 예측 : 용도별, 2020-2034년
    • 종양학
    • 심혈관
    • 중추신경계
    • 혈액질환
  • 시장 매력 분석 : 용도별

제8장 세계의 시장 분석과 예측 : 최종사용자별

  • 소개와 정의
  • 주요 조사 결과·발전
  • 시장 금액 예측 : 최종사용자별, 2020-2034년
    • 제약·바이오테크놀러지 기업
    • CMO와 CDMO
    • 연구 센터 및 학술기관
  • 시장 매력 분석 : 최종사용자별

제9장 세계의 시장 분석과 예측 : 지역별

  • 주요 조사 결과
  • 시장 금액 예측 : 지역별, 2020-2034년
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 매력 분석 : 지역별

제10장 북미의 시장 분석과 예측

제11장 유럽의 시장 분석과 예측

제12장 아시아태평양의 시장 분석과 예측

제13장 라틴아메리카의 시장 분석과 예측

제14장 중동 및 아프리카의 시장 분석과 예측

제15장 경쟁 상황

  • 시장 기업 - 경쟁 매트릭스(기업 계층과 규모별)
  • 시장 점유율 분석 : 기업별(2023년)
  • 기업 개요
    • ViroMed
    • AnGes, Inc.
    • M3 Biotechnology, Inc.
    • AVEO Pharmaceuticals, Inc.
    • Molecular Partners AG
    • YooYoung Pharmaceutical Co., Ltd.
    • F-star Therapeutics Inc.
    • Galaxy Bio Tech
    • Kringle Pharma
ksm 24.09.03

Hepatocyte Growth Factors (HGFs) Market - Scope of Report

TMR's report on the global hepatocyte growth factors (HGFs) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global hepatocyte growth factors (HGFs) market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hepatocyte growth factors (HGFs) market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the hepatocyte growth factors (HGFs) market.

Market Snapshot
Market Value in 2023US$ 70.3 Mn
Market Value in 2034US$ 141 Mn
CAGR6.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hepatocyte growth factors (HGFs) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global hepatocyte growth factors (HGFs) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hepatocyte growth factors (HGFs) market.

The report delves into the competitive landscape of the global hepatocyte growth factors (HGFs) market. Key players operating in the global hepatocyte growth factors (HGFs) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global hepatocyte growth factors (HGFs) market profiled in this report.

Key Questions Answered in Global hepatocyte growth factors (HGFs) Market Report:

  • What is the sales/revenue generated by hepatocyte growth factors (HGFs) across all regions during the forecast period?
  • What are the opportunities in the global hepatocyte growth factors (HGFs) market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Hepatocyte Growth Factors (HGFs) Market - Research Objectives and Research Approach

The comprehensive report on the global hepatocyte growth factors (HGFs) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global hepatocyte growth factors (HGFs) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global hepatocyte growth factors (HGFs) market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Hepatocyte Growth Factors (HGFs) Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2020-2034
    • 6.3.1. Phase III (Ongoing)
    • 6.3.2. Phase II (Approved)
    • 6.3.3. Phase II (Ongoing)
    • 6.3.4. Phase I
    • 6.3.5. Preclinical
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2020-2034
    • 7.3.1. Oncology
    • 7.3.2. Cardiovascular
    • 7.3.3. Central Nervous System
    • 7.3.4. Hematological Disorders
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2020-2034
    • 8.3.1. Pharmaceutical and Biotechnology Companies
    • 8.3.2. CMOs and CDMOs
    • 8.3.3. Research Centers & Academic Institutes
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Type, 2020-2034
    • 10.3.1. Phase III (Ongoing)
    • 10.3.2. Phase II (Approved)
    • 10.3.3. Phase II (Ongoing)
    • 10.3.4. Phase I
    • 10.3.5. Preclinical
  • 10.4. Market Value Forecast, by Application, 2020-2034
    • 10.4.1. Oncology
    • 10.4.2. Cardiovascular
    • 10.4.3. Central Nervous System
    • 10.4.4. Hematological Disorders
  • 10.5. Market Value Forecast, by End-user, 2020-2034
    • 10.5.1. Pharmaceutical and Biotechnology Companies
    • 10.5.2. CMOs and CDMOs
    • 10.5.3. Research Centers & Academic Institutes
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Type
    • 10.7.2. By Application
    • 10.7.3. By End-user
    • 10.7.4. By Country

11. Europe Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Type, 2020-2034
    • 11.3.1. Phase III (Ongoing)
    • 11.3.2. Phase II (Approved)
    • 11.3.3. Phase II (Ongoing)
    • 11.3.4. Phase I
    • 11.3.5. Preclinical
  • 11.4. Market Value Forecast, by Application, 2020-2034
    • 11.4.1. Oncology
    • 11.4.2. Cardiovascular
    • 11.4.3. Central Nervous System
    • 11.4.4. Hematological Disorders
  • 11.5. Market Value Forecast, by End-user, 2020-2034
    • 11.5.1. Pharmaceutical and Biotechnology Companies
    • 11.5.2. CMOs and CDMOs
    • 11.5.3. Research Centers & Academic Institutes
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Application
    • 11.7.3. By End-user
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Type, 2020-2034
    • 12.3.1. Phase III (Ongoing)
    • 12.3.2. Phase II (Approved)
    • 12.3.3. Phase II (Ongoing)
    • 12.3.4. Phase I
    • 12.3.5. Preclinical
  • 12.4. Market Value Forecast, by Application, 2020-2034
    • 12.4.1. Oncology
    • 12.4.2. Cardiovascular
    • 12.4.3. Central Nervous System
    • 12.4.4. Hematological Disorders
  • 12.5. Market Value Forecast, by End-user, 2020-2034
    • 12.5.1. Pharmaceutical and Biotechnology Companies
    • 12.5.2. CMOs and CDMOs
    • 12.5.3. Research Centers & Academic Institutes
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Application
    • 12.7.3. By End-user
    • 12.7.4. By Country/Sub-region

13. Latin America Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Type, 2020-2034
    • 13.3.1. Phase III (Ongoing)
    • 13.3.2. Phase II (Approved)
    • 13.3.3. Phase II (Ongoing)
    • 13.3.4. Phase I
    • 13.3.5. Preclinical
  • 13.4. Market Value Forecast, by Application, 2020-2034
    • 13.4.1. Oncology
    • 13.4.2. Cardiovascular
    • 13.4.3. Central Nervous System
    • 13.4.4. Hematological Disorders
  • 13.5. Market Value Forecast, by End-user, 2020-2034
    • 13.5.1. Pharmaceutical and Biotechnology Companies
    • 13.5.2. CMOs and CDMOs
    • 13.5.3. Research Centers & Academic Institutes
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Application
    • 13.7.3. By End-user
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Type, 2020-2034
    • 14.3.1. Phase III (Ongoing)
    • 14.3.2. Phase II (Approved)
    • 14.3.3. Phase II (Ongoing)
    • 14.3.4. Phase I
    • 14.3.5. Preclinical
  • 14.4. Market Value Forecast, by Application, 2020-2034
    • 14.4.1. Oncology
    • 14.4.2. Cardiovascular
    • 14.4.3. Central Nervous System
    • 14.4.4. Hematological Disorders
  • 14.5. Market Value Forecast, by End-user, 2020-2034
    • 14.5.1. Pharmaceutical and Biotechnology Companies
    • 14.5.2. CMOs and CDMOs
    • 14.5.3. Research Centers & Academic Institutes
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Application
    • 14.7.3. By End-user
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. ViroMed
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. AnGes, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. M3 Biotechnology, Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. AVEO Pharmaceuticals, Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Molecular Partners AG
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. YooYoung Pharmaceutical Co., Ltd.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. F-star Therapeutics Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Galaxy Bio Tech
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Kringle Pharma
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제